| For: | Voutsadakis IA. Molecular predictors of gemcitabine response in pancreatic cancer. World J Gastrointest Oncol 2011; 3(11): 153-164 [PMID: 22110842 DOI: 10.4251/wjgo.v3.i11.153] |
|---|---|
| URL: | https://www.wjgnet.com/1948-5204/full/v3/i11/153.htm |
| Number | Citing Articles |
| 1 |
Komala Ingle, Joseph F. LaComb, Lee M. Graves, Antonio T. Baines, Agnieszka B. Bialkowska, Wagdy Mohamed Eldehna. AUM302, a novel triple kinase PIM/PI3K/mTOR inhibitor, is a potent in vitro pancreatic cancer growth inhibitor. PLOS ONE 2023; 18(11) doi: 10.1371/journal.pone.0294065
|
| 2 |
Adeolu Ogunleye, Chayanit Piyawajanusorn, Ghita Ghislat, Pedro J. Ballester. Large-Scale Machine Learning Analysis Reveals DNA Methylation and Gene Expression Response Signatures for Gemcitabine-Treated Pancreatic Cancer. Health Data Science 2024; 4 doi: 10.34133/hds.0108
|
| 3 |
Daohong Chen, Harikrishna Nakshatri. MicroRNA in Development and in the Progression of Cancer. 2014; doi: 10.1007/978-1-4899-8065-6_16
|
| 4 |
Kyung Hee Jung, Il-Kyu Choi, Hee-Seung Lee, Hong Hua Yan, Mi Kwon Son, Hyo Min Ahn, JinWoo Hong, Chae-Ok Yun, Soon-Sun Hong. Oncolytic adenovirus expressing relaxin (YDC002) enhances therapeutic efficacy of gemcitabine against pancreatic cancer. Cancer Letters 2017; 396 doi: 10.1016/j.canlet.2017.03.009
|
| 5 |
Suresh Chava, Meher B. Gayatri, Aramati B.M. Reddy. Breaking Tolerance to Pancreatic Cancer Unresponsiveness to Chemotherapy. 2019; doi: 10.1016/B978-0-12-817661-0.00003-2
|
| 6 |
Yufeng Zhu, Ming Qi, Lijun Lao, Wei Wang, Luojie Hua, Guang Bai. Human Equilibrative Nucleoside Transporter 1 Predicts Survival in Patients with Pancreatic Cancer Treated with Gemcitabine: A Meta-Analysis. Genetic Testing and Molecular Biomarkers 2014; 18(5) doi: 10.1089/gtmb.2013.0419
|
| 7 |
Hao Li, Wang Jiang, Xue-Ni Liu, Li-Yun Yuan, Tian-Jiao Li, Shuo Li, Shuai-Shuai Xu, Wu-Hu Zhang, He-Li Gao, Xuan Han, Wen-Quan Wang, Chun-Tao Wu, Xian-Jun Yu, Hua-Xiang Xu, Liang Liu. TET1 downregulates epithelial-mesenchymal transition and chemoresistance in PDAC by demethylating CHL1 to inhibit the Hedgehog signaling pathway. Oncogene 2020; 39(36) doi: 10.1038/s41388-020-01407-8
|
| 8 |
Lars Petter Jordheim, Charles Dumontet. Do hENT1 and RRM1 Predict the Clinical benefit of Gemcitabine in Pancreatic Cancer?. Biomarkers in Medicine 2013; 7(4) doi: 10.2217/bmm.13.48
|
| 9 |
Catherine A. Moroski-Erkul, Esin Demir, Esra Gunduz, Mehmet Gunduz. International Manual of Oncology Practice. 2015; doi: 10.1007/978-3-319-21683-6_5
|
| 10 |
Stefanie A. Baril, Tomoka Gose, John D. Schuetz. How Cryo-EM Has Expanded Our Understanding of Membrane Transporters. Drug Metabolism and Disposition 2023; 51(8) doi: 10.1124/dmd.122.001004
|
| 11 |
Patricia Sancho, Sonia Alcala, Valentyn Usachov, Patrick C. Hermann, Bruno Sainz. The ever-changing landscape of pancreatic cancer stem cells. Pancreatology 2016; 16(4) doi: 10.1016/j.pan.2016.04.004
|
| 12 |
Elsa M. Materon, Gustavo F. Nascimento, Flavio M. Shimizu, Amanda S. Câmara, Bianca Sandrino, Ronaldo C. Faria, Osvaldo N. Oliveira. Role of sphingomyelin on the interaction of the anticancer drug gemcitabine hydrochloride with cell membrane models. Colloids and Surfaces B: Biointerfaces 2020; 196 doi: 10.1016/j.colsurfb.2020.111357
|
| 13 |
Nicholas J. Wright, Seok-Yong Lee. Toward a Molecular Basis of Cellular Nucleoside Transport in Humans. Chemical Reviews 2021; 121(9) doi: 10.1021/acs.chemrev.0c00644
|
| 14 |
Xu Zhu, Xiaomeng Shen, Jun Qu, Robert M. Straubinger, William J. Jusko. Multi‐Scale Network Model Supported by Proteomics for Analysis of Combined Gemcitabine and Birinapant Effects in Pancreatic Cancer Cells. CPT: Pharmacometrics & Systems Pharmacology 2018; 7(9) doi: 10.1002/psp4.12320
|
| 15 |
Deepkamal N. Karelia, Sangyub Kim, Manoj K. Pandey, Daniel Plano, Shantu Amin, Junxuan Lu, Arun K. Sharma. Novel Seleno-Aspirinyl Compound AS-10 Induces Apoptosis, G1 Arrest of Pancreatic Ductal Adenocarcinoma Cells, Inhibits Their NF-κB Signaling, and Synergizes with Gemcitabine Cytotoxicity. International Journal of Molecular Sciences 2021; 22(9) doi: 10.3390/ijms22094966
|
| 16 |
John Kaszycki, Jackson C. Lin, Minji Kim, Hunmin Jung. Epigenetic Biomarkers for Predicting Nucleoside Analog Drug Response and Resistance in Cancer. Biomolecules 2026; 16(4) doi: 10.3390/biom16040587
|
| 17 |
Serena Veschi, Maurizio Ronci, Paola Lanuti, Laura De Lellis, Rosalba Florio, Giuseppina Bologna, Luca Scotti, Erminia Carletti, Federica Brugnoli, Maria Cristina Di Bella, Valeria Bertagnolo, Marco Marchisio, Alessandro Cama. Integrative proteomic and functional analyses provide novel insights into the action of the repurposed drug candidate nitroxoline in AsPC-1 cells. Scientific Reports 2020; 10(1) doi: 10.1038/s41598-020-59492-4
|
| 18 |
Sushanta K. Banerjee, Gargi Maity, Inamul Haque, Arnab Ghosh, Sandipto Sarkar, Vijayalaxmi Gupta, Donald R. Campbell, Daniel Von Hoff, Snigdha Banerjee. Human pancreatic cancer progression: an anarchy among CCN-siblings. Journal of Cell Communication and Signaling 2016; 10(3) doi: 10.1007/s12079-016-0343-9
|
| 19 |
A K Thakur, J Nigri, S Lac, J Leca, C Bressy, P Berthezene, L Bartholin, P Chan, E Calvo, J L Iovanna, S Vasseur, F Guillaumond, R Tomasini. TAp73 loss favors Smad-independent TGF-β signaling that drives EMT in pancreatic ductal adenocarcinoma. Cell Death & Differentiation 2016; 23(8) doi: 10.1038/cdd.2016.18
|
| 20 |
Manida Suksawat, Poramate Klanrit, Jutarop Phetcharaburanin, Nisana Namwat, Narong Khuntikeo, Attapol Titapun, Apiwat Jarearnrat, Prakasit Sa-ngiamwibool, Anchalee Techasen, Watcharin Loilome, Gianfranco D. Alpini. In vitro and molecular chemosensitivity in human cholangiocarcinoma tissues. PLOS ONE 2019; 14(9) doi: 10.1371/journal.pone.0222140
|
| 21 |
Zi-Miao Liu, Hong-Yu Tseng, Ya-Ling Cheng, Bi-Wen Yeh, Wen-Jeng Wu, Huei-Sheng Huang. TG-interacting factor transcriptionally induced by AKT/FOXO3A is a negative regulator that antagonizes arsenic trioxide-induced cancer cell apoptosis. Toxicology and Applied Pharmacology 2015; 285(1) doi: 10.1016/j.taap.2015.03.007
|
| 22 |
Silvana Pinotti Muller, Viviane Aline Oliveira Silva, Ana Vitória Pupo Silvestrini, Luana Henrique de Macedo, Guilherme Ferreira Caetano, Rui Manuel Reis, Mauricio Ventura Mazzi. Crotoxin from Crotalus durissus terrificus venom: In vitro cytotoxic activity of a heterodimeric phospholipase A2 on human cancer-derived cell lines. Toxicon 2018; 156 doi: 10.1016/j.toxicon.2018.10.306
|
| 23 |
Li Qin, Zizheng Dong, Caoqinglong Huang, Hao Liu, Jenny Beebe, Boopathi Subramaniyan, Yangyang Hao, Yunlong Liu, Zhimin He, Jing-Yuan Liu, Jian-Ting Zhang. Reversible promoter demethylation of PDGFD confers gemcitabine resistance through STAT3 activation and RRM1 upregulation. Cancer Letters 2023; 567 doi: 10.1016/j.canlet.2023.216266
|
| 24 |
Ioannis A. Voutsadakis. Biomarkers of Trifluridine-Tipiracil Efficacy. Journal of Clinical Medicine 2021; 10(23) doi: 10.3390/jcm10235568
|
| 25 |
Xu Zhu, Xiaomeng Shen, Jun Qu, Robert M. Straubinger, William J. Jusko. Proteomic Analysis of Combined Gemcitabine and Birinapant in Pancreatic Cancer Cells. Frontiers in Pharmacology 2018; 9 doi: 10.3389/fphar.2018.00084
|
| 26 |
Sumit Arora, Arun Bhardwaj, Seema Singh, Sanjeev K. Srivastava, Steven McClellan, Chaitanya S. Nirodi, Gary A. Piazza, William E. Grizzle, Laurie B. Owen, Ajay P. Singh. An Undesired Effect of Chemotherapy. Journal of Biological Chemistry 2013; 288(29) doi: 10.1074/jbc.M113.484576
|
| 27 |
Ioannis A. Voutsadakis. Epithelial to mesenchymal transition in the pathogenesis of uterine malignant mixed Müllerian tumours: the role of ubiquitin proteasome system and therapeutic opportunities. Clinical and Translational Oncology 2012; 14(4) doi: 10.1007/s12094-012-0792-4
|
| 28 |
Ioannis A. Voutsadakis. Ubiquitination and the Ubiquitin–Proteasome System as regulators of transcription and transcription factorsin epithelial mesenchymal transition of cancer. Tumor Biology 2012; 33(4) doi: 10.1007/s13277-012-0355-x
|
| 29 |
Mengmeng Wang, Kunyu Qu, Peipei Zhao, Xin Yin, Yiwei Meng, Piet Herdewijn, Chao Liu, Lixin Zhang, Xuekui Xia. Synthesis and anticancer evaluation of acetylated-lysine conjugated gemcitabine prodrugs. RSC Medicinal Chemistry 2023; 14(8) doi: 10.1039/D3MD00190C
|
| 30 |
Hicham Wahnou, Riad El Kebbaj, Soufyane Hba, Zaynab Ouadghiri, Othman El Faqer, Aline Pinon, Bertrand Liagre, Youness Limami, Raphaël Emmanuel Duval. Neutrophils and Neutrophil-Based Drug Delivery Systems in Anti-Cancer Therapy. Cancers 2025; 17(7) doi: 10.3390/cancers17071232
|
| 31 |
Viviane Silva, Marcela Rosa, Aline Tansini, Renato Oliveira, Olga Martinho, Jo�o Paulo Lima, Luiz Pianowski, Rui Reis. In�vitro screening of cytotoxic activity of euphol from Euphorbia�tirucalli on a large panel of human cancer‑derived cell lines. Experimental and Therapeutic Medicine 2018; doi: 10.3892/etm.2018.6244
|
| 32 |
Lee Cheng Phua, Shixu Goh, David Wai Meng Tai, Wei Qiang Leow, Syed Muhammad Fahmy Alkaff, Chung Yip Chan, Juinn Huar Kam, Tony Kiat Hon Lim, Eric Chun Yong Chan. Metabolomic prediction of treatment outcome in pancreatic ductal adenocarcinoma patients receiving gemcitabine. Cancer Chemotherapy and Pharmacology 2018; 81(2) doi: 10.1007/s00280-017-3475-6
|
| 33 |
Christina H. Wei, Tristan R. Gorgan, David A. Elashoff, O. Joe Hines, James J. Farrell, Timothy R. Donahue. A Meta-Analysis of Gemcitabine Biomarkers in Patients With Pancreaticobiliary Cancers. Pancreas 2013; 42(8) doi: 10.1097/MPA.0b013e3182a23ae4
|
| 34 |
I-Lu Lai, Chih-Chien Chou, Po-Ting Lai, Chun-Sheng Fang, Lawrence A Shirley, Ribai Yan, Xiaokui Mo, Mark Bloomston, Samuel K Kulp, Tanios Bekaii-Saab, Ching-Shih Chen. RETRACTED: Targeting the Warburg effect with a novel glucose transporter inhibitor to overcome gemcitabine resistance in pancreatic cancer cells. Carcinogenesis 2014; 35(10) doi: 10.1093/carcin/bgu124
|
| 35 |
Alexander V. Schperberg, Amélie Boichard, Igor F. Tsigelny, Stéphane B. Richard, Razelle Kurzrock. Machine learning model to predict oncologic outcomes for drugs in randomized clinical trials. International Journal of Cancer 2020; 147(9) doi: 10.1002/ijc.33240
|
| 36 |
Ting Zhan, Xiaoli Chen, Xia Tian, Zheng Han, Meng Liu, Yanli Zou, Shasha Huang, Aifang Chen, Xueting Cheng, Junsheng Deng, Jie Tan, Xiaodong Huang. MiR-331-3p Links to Drug Resistance of Pancreatic Cancer Cells by Activating WNT/β-Catenin Signal via ST7L. Technology in Cancer Research & Treatment 2020; 19 doi: 10.1177/1533033820945801
|
| 37 |
Sarrah L. Hasanali, Daley S. Morera, Ronny R. Racine, Martin Hennig, Santu Ghosh, Luis E. Lopez, Marie C. Hupe, Diogo O. Escudero, Jiaojiao Wang, Huabin Zhu, Semih Sarcan, Ijeoma Azih, Michael Zhou, Andre R. Jordan, Martha K. Terris, Markus A. Kuczyk, Axel S. Merseburger, Vinata B. Lokeshwar. HYAL4-V1/Chondroitinase (Chase) Drives Gemcitabine Resistance and Predicts Chemotherapy Failure in Patients with Bladder Cancer. Clinical Cancer Research 2021; 27(15) doi: 10.1158/1078-0432.CCR-21-0422
|
| 38 |
Shwetapadma Dash, Sonali Sahoo, Sanjeeb Kumar Sahoo. Recent Advances in Nanocarriers for Pancreatic Cancer Therapy. 2024; doi: 10.1016/B978-0-443-19142-8.00017-6
|
| 39 |
Adam Markowski, Anna Jaromin, Paweł Migdał, Ewa Olczak, Adrianna Zygmunt, Magdalena Zaremba-Czogalla, Krzysztof Pawlik, Jerzy Gubernator. Design and Development of a New Type of Hybrid PLGA/Lipid Nanoparticle as an Ursolic Acid Delivery System against Pancreatic Ductal Adenocarcinoma Cells. International Journal of Molecular Sciences 2022; 23(10) doi: 10.3390/ijms23105536
|
| 40 |
WAREEPORN WATTANAWONGDON, CHARIYA HAHNVAJANAWONG, NISANA NAMWAT, SIRIMAS KANCHANAWAT, THIDARUT BOONMARS, PATCHAREE JEARANAIKOON, CHANWIT LEELAYUWAT, ANCHALEE TECHASEN, WUNCHANA SEUBWAI. Establishment and characterization of gemcitabine-resistant human cholangiocarcinoma cell lines with multidrug resistance and enhanced invasiveness. International Journal of Oncology 2015; 47(1) doi: 10.3892/ijo.2015.3019
|
| 41 |
Catherine A. Moroski-Erkul, Esin Demir, Esra Gunduz, Mehmet Gunduz. International Manual of Oncology Practice. 2019; doi: 10.1007/978-3-030-16245-0_5
|
| 42 |
Xu Zhu, Robert M. Straubinger, William J. Jusko. Mechanism-based mathematical modeling of combined gemcitabine and birinapant in pancreatic cancer cells. Journal of Pharmacokinetics and Pharmacodynamics 2015; 42(5) doi: 10.1007/s10928-015-9429-x
|
| 43 |
Jung Won Chun, Boyoung Lee, Weon Seo Park, Nayoung Han, Eun Kyung Hong, Eun Young Park, Sung Sik Han, Sang-Jae Park, Tae Hyun Kim, Woo Jin Lee, Sang Myung Woo. RRM1 Expression as a Prognostic Biomarker for Unresectable or Recurrent Biliary Tract Cancer Treated with Gemcitabine plus Cisplatin. Journal of Clinical Medicine 2021; 10(20) doi: 10.3390/jcm10204652
|
| 44 |
Ioannis A. Voutsadakis. The chemosensitivity of testicular germ cell tumors. Cellular Oncology 2014; 37(2) doi: 10.1007/s13402-014-0168-6
|
| 45 |
P.S. Sushma, Ganji Purnachandra Nagaraju. Breaking Tolerance to Pancreatic Cancer Unresponsiveness to Chemotherapy. 2019; doi: 10.1016/B978-0-12-817661-0.00004-4
|
| 46 |
Foong Ying Wong, Natalia Liem, Chen Xie, Fui Leng Yan, Wing Cheong Wong, Lingzhi Wang, Wei-Peng Yong, Joseph Alan Bauer. Combination Therapy with Gossypol Reveals Synergism against Gemcitabine Resistance in Cancer Cells with High BCL-2 Expression. PLoS ONE 2012; 7(12) doi: 10.1371/journal.pone.0050786
|
| 47 |
Nicholas J. Wright, Seok-Yong Lee. Structures of human ENT1 in complex with adenosine reuptake inhibitors. Nature Structural & Molecular Biology 2019; 26(7) doi: 10.1038/s41594-019-0245-7
|
| 48 |
John Kaszycki, Minji Kim. Epigenetic Drivers of Chemoresistance in Nucleobase and Nucleoside Analog Therapies. Biology 2025; 14(7) doi: 10.3390/biology14070838
|
| 49 |
Suparna Qanungo, Joachim D. Uys, Yefim Manevich, Anne M. Distler, Brooke Shaner, Elizabeth G. Hill, John J. Mieyal, John J. Lemasters, Danyelle M. Townsend, Anna-Liisa Nieminen. N-acetyl-l-cysteine sensitizes pancreatic cancers to gemcitabine by targeting the NFκB pathway. Biomedicine & Pharmacotherapy 2014; 68(7) doi: 10.1016/j.biopha.2014.08.007
|
| 50 |
Jing Cui, Yao Guo, Heshui Wu, Jiongxin Xiong, Tao Peng. Everolimus regulates the activity of gemcitabine-resistant pancreatic cancer cells by targeting the Warburg effect via PI3K/AKT/mTOR signaling. Molecular Medicine 2021; 27(1) doi: 10.1186/s10020-021-00300-8
|
| 51 |
Piyush Bugde, Riya Biswas, Fabrice Merien, Jun Lu, Dong-Xu Liu, Mingwei Chen, Shufeng Zhou, Yan Li. The therapeutic potential of targeting ABC transporters to combat multi-drug resistance. Expert Opinion on Therapeutic Targets 2017; 21(5) doi: 10.1080/14728222.2017.1310841
|
| 52 |
Jesse Pulido, Adam J. Sobczak, Jan Balzarini, Stanislaw F. Wnuk. Synthesis and Cytostatic Evaluation of 4-N-Alkanoyl and 4-N-Alkyl Gemcitabine Analogues. Journal of Medicinal Chemistry 2014; 57(1) doi: 10.1021/jm401586a
|
| 53 |
Paola Lecca. An integrative network inference approach to predict mechanisms of cancer chemoresistance. Integrative Biology 2013; 5(3) doi: 10.1039/c2ib20205k
|
| 54 |
Li Qin, Zizheng Dong, Jian-Ting Zhang. Reversible Epigenetic Regulation of 14-3-3σ Expression in Acquired Gemcitabine Resistance by Uhrf1 and DNA Methyltransferase 1. Molecular Pharmacology 2014; 86(5) doi: 10.1124/mol.114.092544
|
| 55 |
Shuang Liu, Yubin Ge, Tingting Wang, Holly Edwards, Qihang Ren, Yiqun Jiang, Chengshi Quan, Guan Wang. Inhibition of ATR potentiates the cytotoxic effect of gemcitabine on pancreatic cancer cells through enhancement of DNA damage and abrogation of ribonucleotide reductase induction by gemcitabine. Oncology Reports 2017; 37(6) doi: 10.3892/or.2017.5580
|
| 56 |
Ting Zhan, Xiaodong Huang, Xia Tian, Xiaoli Chen, Yu Ding, Hesheng Luo, Yadong Zhang. Downregulation of MicroRNA-455-3p Links to Proliferation and Drug Resistance of Pancreatic Cancer Cells via Targeting TAZ. Molecular Therapy Nucleic Acids 2018; 10 doi: 10.1016/j.omtn.2017.12.002
|
| 57 |
Athina Stravodimou, Gianluigi Mazzoccoli, Ioannis A. Voutsadakis. Peroxisome Proliferator-Activated Receptor Gamma and Regulations by the Ubiquitin-Proteasome System in Pancreatic Cancer. PPAR Research 2012; 2012 doi: 10.1155/2012/367450
|
| 58 |
Li Qin, Zizheng Dong, Jian-Ting Zhang. 14-3-3σ regulation of and interaction with YAP1 in acquired gemcitabine resistance via promoting ribonucleotide reductase expression. Oncotarget 2016; 7(14) doi: 10.18632/oncotarget.7394
|
| 59 |
Amber Blaauboer, Stephanie Booy, Peter M. van Koetsveld, Bas Karels, Fadime Dogan, Suzanne van Zwienen, Casper H. J. van Eijck, Leo J. Hofland. Interferon-beta enhances sensitivity to gemcitabine in pancreatic cancer. BMC Cancer 2020; 20(1) doi: 10.1186/s12885-020-07420-0
|
| 60 |
XI ZHENG, XIAO-XING CUI, ZHI GAO, MICHAEL VERANO, MOU-TUAN HUANG, YUE LIU, ARNOLD B. RABSON, ALLAN H. CONNEY. Effects of 12-O-tetradecanoylphorbol-13-acetate in combination with gemcitabine on Panc-1 pancreatic cancer cells cultured in vitro or Panc-1 tumors grown in immunodeficient mice. International Journal of Oncology 2012; 41(6) doi: 10.3892/ijo.2012.1651
|
| 61 |
Ozan Kahramanoğullari, Gianluca Fantaccini, Paola Lecca, Daniele Morpurgo, Corrado Priami, Raya Khanin. Algorithmic Modeling Quantifies the Complementary Contribution of Metabolic Inhibitions to Gemcitabine Efficacy. PLoS ONE 2012; 7(12) doi: 10.1371/journal.pone.0050176
|
| 62 |
Daniel Braas, Ethan Ahler, Brenna Tam, David Nathanson, Mirielle Riedinger, Matthias R. Benz, Kathleen B. Smith, Fritz C. Eilber, Owen N. Witte, William D. Tap, Hong Wu, Heather R. Christofk. Metabolomics Strategy Reveals Subpopulation of Liposarcomas Sensitive to Gemcitabine Treatment. Cancer Discovery 2012; 2(12) doi: 10.1158/2159-8290.CD-12-0197
|
| 63 |
Azam Rajabpour, Farzad Rajaei, Ladan Teimoori-Toolabi. Molecular alterations contributing to pancreatic cancer chemoresistance. Pancreatology 2017; 17(2) doi: 10.1016/j.pan.2016.12.013
|